Abstract: The invention relates to a stable solid dosage form comprising olmesartan medoxomil and amlodipine or a pharmacologically acceptable salt thereof. In particular, it relates to solid dosage forms free from reducing sugars. The stable solid dosage form may optionally further comprise hydrochlorothiazide or a pharmacologically acceptable salt thereof.

Abstract: The invention relates to a stable solid dosage form comprising olmesartan medoxomil and amlodipine or a pharmacologically acceptable salt thereof. In particular, it relates to solid dosage forms free from reducing sugars. The stable solid dosage form may optionally further comprise hydrochlorothiazide or a pharmacologically acceptable salt thereof.

Abstract: Topically applicable pharmaceutical/therapeutic alcoholic solution compositions, well suited for percutaneous/transdermal antithrombotic therapy, comprise an effective antithrombotic amount of acetylsalicylic acid ("ASA") or salt thereof, formulated into primary alcohol (e.g., isopropanol) and secondary ester (e.g., isopropyl myristate) solvents therefor, optionally in the presence of penetration enhancers and/or ASA hydrolysis inhibitors.

Abstract: The present invention relates to a device for the topical and systemic administration of active substances to or through the skin consisting of a backing layer, at least one self-adhesive layer, and a removable protective layer, wherein the self-adhesive layer consists of(a) 100 parts by weight of a polyacrylate adhesive,(b) 5 to 150, preferably 10 to 100, and in particular 15 to 50 parts by weight of a film former compatible with polyacrylates,(c) 0 to 250 parts by weight of a non-softening active substance and/or adjuvant, and(d) 10 to 250 parts by weight of a softening active substance and/or adjuvant.